OOIR: Observatory of International Research

Papers

(The H4-Index of Hepatology International is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease	399
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)	189
How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?	140
Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis	99
Liver injury in remdesivir-treated COVID-19 patients	91
Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study	91
Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis	85
Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis	82
Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases	65
The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995–2040	65
Liver transplantation and COVID-19 (Coronavirus) infection: guidelines of the liver transplant Society of India (LTSI)	62
Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines	59
Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations	59
Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma	58
Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders	57
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy	56
Liver injury in patients with COVID-19: clinical profiles, CT findings, the correlation of the severity with liver injury	56
Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial	51
Current perspectives on the tumor microenvironment in hepatocellular carcinoma	47
Effect of COVID-19 on patients with compensated chronic liver diseases	47
Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation	46
Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?	42
APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients	42
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis	41
Spleen stiffness measurement for assessing the response to β-blockers therapy for high-risk esophageal varices patients	40

Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis (FRISC study): a randomized controlled trial	40
Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL)	38
Intestinal failure-associated liver disease (IFALD): insights into pathogenesis and advances in management	38
A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC	38
HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort	38
Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis	37
The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis	37
Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group	36
Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial	34
The role of neutrophils in innate immunity-driven nonalcoholic steatohepatitis: lessons learned and future promise	34